NGHIÊN CỨU ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ TRẺ DẬY THÌ SỚM TRUNG ƯƠNG VÔ CĂN

Abstract

Introduction: Precocious puberty means the appearance of secondary sexual characteristics (breast development, pubic hair system, armpit hair, testicles, penis, acne...) before age 8 in girls or menstruation before age 9.5 in girls and before age 9 in boys¹. The number of children with precocious puberty is increasing. It is expected to grow in the coming years, greatly affecting children's psychological and physical health. Objectives: Describe clinical and paraclinical characteristics and survey the treatment results of idiopathic central precocious puberty with Triptoreline. Subjects and methods: Cross-sectional description, prospective. Subjects: 32 girls diagnosed with idiopathic central precocious puberty and treated with Diphereline 3.75 mg continuously for 6 months from June 2023 to October 2024. Results: The average age is 7.28±0.58, the age group from 6 years old - < 8 years old accounts for 2/3 (65.6%). 100% of girls have breast development from Tanner stage 2 or higher, B2 (71.90%). Average time from first symptom appearance: 7.33 ± 3.34 months. LH and FSH concentrations from 0.93±1.42 UI/L and 3.48±3.19 UI/L to 0.52±0.40 UI/L and 1.14±0.73 UI/L. After 6 months of treatment, the average height increased by 2.25 cm compared to before treatment. The estimated adult height development is 1.51 (cm). Conclusion: Treatment of central precocious puberty with Triptoreline: Inhibits and stops the development of mammary glands, menstruation and pubic hair development. Basal LH and FSH concentrations decreased, which was statistically significant after 6 months of treatment. The predicted adult height boosts.